Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
St. Luke's Medical Center
mi
from
Milwaukee, WI
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Hopital Minjoz
mi
from
Besancon,
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Hopital Minjoz
mi
from
Besancon,
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
University Medical Center
mi
from
Tucson, AZ
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Northside Hospital and Heart Institute
mi
from
Saint Petersburg, FL
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Northside Hospital and Heart Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Saint Louis University Hospital
mi
from
Saint Louis, MO
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Saint Louis University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Saint Louis University
mi
from
Saint Louis, MO
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Des Peres Hospital
mi
from
Saint Louis, MO
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Des Peres Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated:  2/20/2018
Mount Sinai Hosp
mi
from
New York, NY
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Status: Enrolling
Updated: 2/20/2018
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease
Status: Enrolling
Updated:  2/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease
Status: Enrolling
Updated: 2/21/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)
Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome
Status: Enrolling
Updated:  2/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)
Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome
Status: Enrolling
Updated: 2/21/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
The Holding Area LINQ (Reveal LINQ Insertable Cardiac Monitor) Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial
The Holding Area LINQ Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial Designed to Occur in the Holding Area of a Hospital Operating Room or Cardiac Catheterization/Electrophysiology Laboratory
Status: Enrolling
Updated:  2/21/2018
Jim Moran Heart and Vascular Research Institute
mi
from
Fort Lauderdale, FL
The Holding Area LINQ (Reveal LINQ Insertable Cardiac Monitor) Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial
The Holding Area LINQ Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial Designed to Occur in the Holding Area of a Hospital Operating Room or Cardiac Catheterization/Electrophysiology Laboratory
Status: Enrolling
Updated: 2/21/2018
Jim Moran Heart and Vascular Research Institute
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated:  2/21/2018
John C. Lincoln Heart Institute
mi
from
Phoenix, AZ
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated: 2/21/2018
John C. Lincoln Heart Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated:  2/21/2018
Piedmont Heart Institute
mi
from
Blue Ridge, GA
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated: 2/21/2018
Piedmont Heart Institute
mi
from
Blue Ridge, GA
Click here to add this to my saved trials
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated:  2/21/2018
Heart Associates
mi
from
Youngstown, OH
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
Status: Enrolling
Updated: 2/21/2018
Heart Associates
mi
from
Youngstown, OH
Click here to add this to my saved trials
Beverages and Societal Health
Sugar Sweetened Beverages And Cardiovascular Disease Risk
Status: Enrolling
Updated:  2/27/2018
Children's Hospital Boston
mi
from
Boston, MA
Beverages and Societal Health
Sugar Sweetened Beverages And Cardiovascular Disease Risk
Status: Enrolling
Updated: 2/27/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Carl T. Hayden Veterans Affairs Medical Center
mi
from
Phoenix, AZ
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Carl T. Hayden Veterans Affairs Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Dr. Wiliam M. Scholl College of Podiatric Medicine
mi
from
North Chicago, IL
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Dr. Wiliam M. Scholl College of Podiatric Medicine
mi
from
North Chicago, IL
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Endeavor Clinical Trials, PA
mi
from
San Antonio, TX
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Endeavor Clinical Trials, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
UCLA
mi
from
Los Angeles, CA
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
University of North Carolina School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
University of Virginia
mi
from
Charlottesville, VA
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
University of Wisconsin
mi
from
Madison, WI
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated:  2/27/2018
Complete Family Foot Care - McAllen Office
mi
from
McAllen, TX
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer
Status: Enrolling
Updated: 2/27/2018
Complete Family Foot Care - McAllen Office
mi
from
McAllen, TX
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
Keck Medical Center of USC
mi
from
Los Angeles, CA
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
Keck Medical Center of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
Miami Cardiac and Vascular Institute
mi
from
Miami, FL
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
Miami Cardiac and Vascular Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
Good Samaritan Hospital
mi
from
Cincinnati, OH
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
Good Samaritan Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
Miami Valley Hospital
mi
from
Dayton, OH
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
Methodist Hospital
mi
from
Houston, TX
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated:  2/27/2018
University Hospital of Strasbourg
mi
from
Strasbourg,
Registry of the Magellan Robotic System
The Robotic Vascular and Endovascular Registry (ROVER)
Status: Enrolling
Updated: 2/27/2018
University Hospital of Strasbourg
mi
from
Strasbourg,
Click here to add this to my saved trials
Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Safety, Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Status: Enrolling
Updated:  2/27/2018
University of Pennsylvania Health Systems
mi
from
Philadelphia, PA
Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Safety, Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Status: Enrolling
Updated: 2/27/2018
University of Pennsylvania Health Systems
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mindful Hearts Study
Mindfulness Based Stress Reduction for Women at Risk for Cardiovascular Disease
Status: Enrolling
Updated:  3/2/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
Mindful Hearts Study
Mindfulness Based Stress Reduction for Women at Risk for Cardiovascular Disease
Status: Enrolling
Updated: 3/2/2018
Edward Hines Jr. VA Hospital, Hines, IL
mi
from
Hines, IL
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
Arizona Heart Hospital / Abrazo Health Care Research / Tenet Health
mi
from
Phoenix, AZ
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
Arizona Heart Hospital / Abrazo Health Care Research / Tenet Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
Cardiovascular Medical Group of Southern California / Cardiovascular Research Foundation
mi
from
Beverly Hills, CA
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
Cardiovascular Medical Group of Southern California / Cardiovascular Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
St. Joseph Hospital of Orange Heart and Vascular Center
mi
from
Orange, CA
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
St. Joseph Hospital of Orange Heart and Vascular Center
mi
from
Orange, CA
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
San Francisco VA Medical Center
mi
from
San Francisco, CA
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
San Francisco VA Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
VA Eastern Colorado Healthcare System
mi
from
Denver, CO
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
VA Eastern Colorado Healthcare System
mi
from
Denver, CO
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
The Hartford Hospital
mi
from
Hartford, CT
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
MedStar Health Washington Hospital Center
mi
from
Washington,
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
MedStar Health Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
First Coast Cardiovascular Institute
mi
from
Jacksonville, FL
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
First Coast Cardiovascular Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
Munroe Regional Medical Center
mi
from
Ocala, FL
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
Munroe Regional Medical Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
Coastal Vascular & Interventional, PLLC.
mi
from
Pensacola, FL
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
Coastal Vascular & Interventional, PLLC.
mi
from
Pensacola, FL
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
St. Joseph Hospital
mi
from
Fort Wayne, IN
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
St. Joseph Hospital
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
Willis Knighton Medical Center
mi
from
Shreveport, LA
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
Willis Knighton Medical Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated:  3/6/2018
St. John Providence Hospital and Medical Center
mi
from
Detroit, MI
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Status: Enrolling
Updated: 3/6/2018
St. John Providence Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials